Luven Diagnostic ICO

Unique cancer diagnostic technology

The LUVEN screening test method created by scientist of our company detects cancer at its early stages with the accuracy of up to 96% only comparable to biopsy. None of the existing diagnostic techniques has such a high diagnostic accuracy. The LUVEN technology allows diagnosing the disease at its early stages , thus, giving a chance to thousands of people to prevent its further development.

3.0 out of 5

3.0

Luven Diagnostic ICO rating
Luven Diagnostic coin (token) sale
Status
Active
ICO start date:
2018-01-15
ICO end date:
2018-02-28
Token
LVN
Price
Platform
Ethereum
Accepting
ETH
Soft cap
Undefined
Hard cap
Undefined
ICO country
Ukraine

Go to the site

About Luven Diagnostic ICO

The LUVEN screening test method created by scientist of our company detects cancer at its early stages with the accuracy of up to 96% only comparable to biopsy. None of the existing diagnostic techniques has such a high diagnostic accuracy.

The LUVEN technology allows to diagnose the disease at its early stages, thus, giving a chance to thousands of people to prevent its further development.

For more than 20 years the Ukrainian scientists have been developing a diagnostic method based on cyto-morphological and cyto-biophysical properties of the buccal epithelial cells. In 2004 at Fenix Cancer Research Center, they continued their research and, finally, came up and implemented an experimental method. A new method of biomaterial analysis allowed to establish a cancer diagnosis at its early stages and to assess predisposition to cancer. A great success in this medical field opened a door to new possibilities,including cancer prevention and therapy. The longstanding scientific research in this field culminated in development of The Luven diagnostic system.

Why is it critical to detect cancer in its early stage?
Around 10 mln people worldwide are annually diagnosed with cancer, with every third patient dying from it. One of the main reasons of such a high mortality rate is late diagnosis.

According to statistics:

  • after treatment in stage 1 cancer — around 93% of patients survive;
  • stage 2 cancer — around 75% survive;
  • stage 3 cancer — 55% survive;
  • stage 4 cancer — only 13% survive;

This is why one should get a check-up as often as possible, thus preventing the disease progression.

Regardless of the rapid development of modern medicine and biology cancer, annually, takes millions of human lives. One cancer patient, worldwide, dies from this disease every 30 seconds.

The key to successful cancer treatment is early diagnosis.

Our History

The development of this method started in early 1983 at the research institute, chair for genetics. Based on the cellular theory by Rudolf Vichow, a team of scientists was working on a diagnostic method and studying buccal cells. Ms. Galina Shchukina, a genetic scientist and cytologist, was at the head of the scientific research. She conducted an in-depth study of scientific papers describing a new biophysical concept of the gene activity regulation based on the role of relationship between homologous chromosomes and genome. Together with Mr. Alexander Shchukin, a nuclear physicist, they invented an ion trap allowing to estimate bioelectric charge of cells. Further research and studies of this concept laid the basis for a new diagnostic method born in 2004, according to which any changes in the human body reflect on cells, including buccal epithelial cells. It was the first milestone in the developm

Luven Diagnostic Team

Alexander Danilchenko

CEO

Nikolay Shchukin

Postgraduate Student of Chair for Biomedical Engineering

Aleksander Shchukin

Nuclear Physician

Galina Shchukina

Geneticist & Cytologist

Grigory Evglevskiy

CTO

Alexander Kamensky

Principal Software Engineer

Yana Ivchenko

PR Manager


Luven Diagnostic Roadmap

1983

Development ofthe cancer diagnostic method started, based on the study of buccal cells (cells from the inside ofthe cheek)

2004

A cytomorphobiologial diagnostic method appeared which formed the basis ofthe diagnostic complex

2010

Team expansion. A commercial enterprise promoting the LUVEN trademark was established. The software automating a part ofthe diagnostic procedure was created.

2014

The diagnostic method was patented, completion of the clinicaltrials, creation ofthe software diagnostic complex presented at two international medical exhibitions “The 5th International Medical Forum” and “Health Care 2014”. Opening first franchise outlets.

2015

In five months after launching a franchise, the contracts were signed with more than twenty outlets, half of which have already run tests on more than two thousand patients. Suspension of activities for a time allowing technology enhancement.

2016 - 2017

Software enhancement, additional clinicaltrials. Optimizing a big number ofthe system algorithms

September - October 2017

Preparing and starting a preICO aimed at fundraising for the software enhancement, legal costs and operational expenses ofthe project

January 2018

Starting an ICO

2018

Further software enhancement, signing contracts with clinics worldwide for conducting clinicaltrials, opening a research center in Austria. Initiating certification ofthe method in the European Union and Eurasian Union

2019

Opening 20 new labs in the European Union and Eurasian Union, incorporating a blockchain and developing a domestic exchange for token sale, working on the optical recognition of incoming images ofthe cell, creating a database of patients and their test results for monitoring tendencies and informing patients on the necessity of being diagnosed

2020

Starting clinicaltrials and certification in the USA and Asia

2021

Developing home gadgets (a home lab) for running tests on the entire family at any time, launching the product.

Financial

Luven Diagnostic token info

Token LVN
Platform Ethereum

Coin price Undefined

Investment info

Accepting ETH
Equity on offer Undefined

User review


0 reviews
You need to to post a review.

Share this project with your friends